TILRAY MEDICAL
DEAD

Serial Number

97433023

Owner

Tilray Brands, Inc.

Attorney

PETER SLOANE

Filing Date

May 27, 2022

Add to watchlist:

No watchlists yet
View on USPTO

TILRAY MEDICAL Trademark

Serial Number: 97433023

TILRAY MEDICAL is a trademark filed by Tilray Brands, Inc. on May 27, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 31 (Natural Agricultural Products). The application is currently no longer active.

Owner Contact Info

Tilray Brands, Inc.

19th Floor
New York, NY 10065

Entity Type: 03

Trademark Details

Filing Date

May 27, 2022

Registration Date

Not Registered

Goods & Services

Providing the breeding, growing, cultivation, and harvesting of cannabis for others; production of cannabis, namely, cultivation of cannabis plants, for others; none of the foregoing services featuring or providing cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of more than 0.3 percent on a dry weight basis

Live cannabis plants; Cannabis seeds for agricultural purposes; derived solely from hemp plants containing no more than .3 percent delta-9 tetrahydrocannabinol (THC) concentration by dry weight basis

Research services, namely, medical, scientific, foods, cosmetic, product, and agricultural research in the area of cannabis, cannabis related products, derivatives of cannabis, and natural health products containing cannabis; none of the foregoing services featuring or providing cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of more than 0.3 percent on a dry weight basis

Cannabis related products, namely, medicated oils, salves, tinctures, tablets and capsules, each containing cannabis for medicinal purposes for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; oils, salves, tinctures, tablets and capsules each containing resins and oils derived from cannabis for medicinal purposes for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; nutraceuticals for medicinal purposes for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; nutraceuticals for medicinal purposes containing cannabis for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; nutraceuticals for medicinal purposes containing derivatives of cannabis, namely, resins and oils for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; medicated topical skin creams, bar and liquid soaps, bath additives, bath herbs, bath oils, body creams, body oils, face and body lotions, face and body milk, face lotion, and skin care preparations each containing derivatives of cannabis, for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; personal sexual lubricants; transdermal patches containing cannabis for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; oral sprays containing cannabis for medicinal use for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; cannabis for medicinal purposes, namely, gummy vitamins for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; cannabis related product, namely, oils for medicinal use for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; oils derived from cannabis for medicinal use for the relief of pain, for relaxation, for reducing stress and fatigue, for mood enhancement, for maintaining general health and well-being, for relieving anxiety, for relieving depression, as a sleep aid and for management of opioid addiction and relief of epilepsy; none of the foregoing containing cannabis with a delta-9 tetrahydrocannabinol (THC) concentration of more than 0.3 percent on a dry weight basis

Providing entertainment information in the field of cannabis culture via a website; providing news via a website in the nature of current event reporting in the field of cannabis and cannabis culture; providing educational information in the field of cannabis-themed cultural events and festivals via a website

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Apr 21, 2026 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Apr 21, 2026 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 5, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jan 5, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jan 5, 2026 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 8, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 8, 2025 CRFA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 8, 2025 CHAN
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Dec 4, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Oct 2, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Oct 2, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Oct 2, 2025 CNSI
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 14, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 14, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 14, 2025 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 5, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 5, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 5, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 5, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 5, 2025 COAR
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 4, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 4, 2025 GNSL
SUSPENSION LETTER WRITTEN
Apr 4, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 4, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 4, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 3, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 16, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 16, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 16, 2025 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 18, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 18, 2024 GNSL
SUSPENSION LETTER WRITTEN
Jul 18, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 17, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 17, 2024 CRFA
ASSIGNED TO LIE
Jul 17, 2024 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jan 30, 2024 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Nov 16, 2023 GNS2
INQUIRY TO SUSPENSION E-MAILED
Nov 16, 2023 GNSI
SUSPENSION INQUIRY WRITTEN
Nov 16, 2023 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 19, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
May 19, 2023 GNSL
SUSPENSION LETTER WRITTEN
May 19, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 26, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 25, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 25, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 31, 2022 GNRN
NON-FINAL ACTION E-MAILED
Oct 31, 2022 GNRT
NON-FINAL ACTION WRITTEN
Oct 31, 2022 CNRT
ASSIGNED TO EXAMINER
Oct 24, 2022 DOCK
ASSIGNED TO EXAMINER
Aug 1, 2022 DOCK
ASSIGNED TO EXAMINER
Aug 1, 2022 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jun 4, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 3, 2022 NWOS
NEW APPLICATION ENTERED
May 31, 2022 NWAP